Collegium 2024 guidance: revenue $580-595M, adj. EBITDA $380-395M, $150M buyback

COLLEGIUM PHARMACEUTICAL, INC

2023-FY EPS reported $1.29 revenue$566,767,000

FY2024 product revenue net expected $580M-$595M; adjusted EBITDA $380M-$395M.
Board authorized $150M share repurchase program through June 30, 2025.
Xtampza ER gross-to-net improving to 56%-58% after renegotiations covering 30% of scripts.
Belbuca renegotiated major Medicare Part D contract, reducing rebate, and won new plan (~1M lives).
Returned $75M to shareholders in 2023 under prior buyback, including $25M accelerated repurchase.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.